ArticleBone & joint research2026
Unveiling the association between low-density lipoprotein cholesterol lowering and fracture risk : real-world evidence from a target trial emulation study.
Article in Bone & joint research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: High serum low-density lipoprotein cholesterol (LDL-C) levels are associated with increased risk of fracture; however, it remains unclear whether lowering LDL-C reduces fracture risk, and, if so, whether the magnitude of LDL-C reduction is linearly associated with fracture risk. This study aimed to evaluate the relation between the degree of LDL-C reduction and fracture risk. Methods: This population-based cohort study included individuals aged 40 to 90 years who initiated statins for hyperlipidaemia from IQVIA Medical Research Data primary care database in the UK (2000 to 2022). The primary outcome was hip fracture. Secondary outcomes included composite fracture and major osteoporotic fracture. A hypothetical target trial was emulated to assess the effect of achieving a LDL-C level of 1.8 to 2.6 mmol/L or < 1.8 mmol/L versus > 2.6 mmol/L induced by statin initiation within one year on the risk of incident and recurrent fractures over five years. Results: Among 165,242 people with hyperlipidaemia initiating statins (mean age 62.6 years, 51.1% female), the five-year risk of incident hip fracture was lower in the 1.8 to 2.6 mmol/L arm (0.53%) and in the < 1.8 mmol/L arm (0.52%) than the > 2.6 mmol/L LDL-C arm (0.65%). The corresponding hazard ratios (HRs) were 0.77 (95% CI 0.65 to 0.91) and 0.68 (95% CI 0.54 to 0.86), respectively. A similar decreased risk of recurrent hip fracture was observed for the 1.8 to 2.6 mmol/L arm (HR = 0.79, 95% CI 0.39 to 1.58) and < 1.8 mmol/L arm (HR = 0.32, 95% CI 0.15 to 0.66), respectively. Additionally, lowering LDL-C levels reduced the risks of composite fracture and major osteoporotic fracture. Conclusion: In this population-based cohort study, LDL-C lowering was associated with a decreased risk of fracture in individuals with hyperlipidaemia. This decreased risk appeared to be associated with the extent of LDL-C lowering, suggesting that the therapeutic paradigm of 'lower is better' could be advantageous for fracture prevention in individuals with hyperlipidaemia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.